NUC-1031 in Patients With Advanced Solid Tumours

PHASE1CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Cancer
Interventions
DRUG

NUC-1031

Cohort 1, Schedule A, NUC-1031 I.V. 1000mg/m2, Days 1, 8, \& 15 every 28 days Cohort 1, Schedule B, NUC-1031 I.V. 500mg/m2, Days 1 \& 5, 8 \& 12, 15 \&19 every 28 days Cohort 2, Schedule A, NUC-1031 I.V. 2000mg/m2, Days 1, 8, \& 15 every 28 days Cohort 2, Schedule B, NUC-1031 I.V. 1000mg/m2, Days 1 \& 5, 8 \& 12, 15 \&19 every 28 days

Trial Locations (1)

W12 0HS

NIHR/Wellcome Trust Imperial CRF, London

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Nucana

UNKNOWN

lead

Imperial College London

OTHER